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Borrelia burgdorferi elongation factor EF-Tu is an
immunogenic protein during Lyme borreliosis
Sebastian E Carrasco1, Youyun Yang1, Bryan Troxell1, Xiuli Yang2, Utpal Pal2 and X Frank Yang1
Borrelia burgdorferi, the etiological agent of Lyme disease, does not produce lipopolysaccharide but expresses a large number of
lipoproteins on its cell surface. These outer membrane lipoproteins are highly immunogenic and have been used for serodiagnosis of
Lyme disease. Recent studies have shown that highly conserved cytosolic proteins such as enolase and elongation factor Tu (EF-Tu)
unexpectedly localized on the surface of bacteria includingB. burgdorferi, and surface-localized enolase has shown to contribute to the
enzootic cycle of B. burgdorferi. In this study, we studied the immunogenicity, surface localization, and function of B. burgdorferi
EF-Tu. We found that EF-Tu is highly immunogenic in mice, and EF-Tu antibodies were readily detected in Lyme disease patients. On
the other hand, active immunization studies showed that EF-Tu antibodies did not protect mice from infection when challenged with
B. burgdorferi via either needle inoculation or tick bites. Borrelial mouse-tick cycle studies showed that EF-Tu antibodies also did not
block B. burgdorferi migration and survival in ticks. Consistent with these findings, we found that EF-Tu primarily localizes in the
protoplasmic cylinder of spirochetes and is not on the surface ofB. burgdorferi. Taken together, our studies suggest thatB. burgdorferi
EF-Tu is not surfaced exposed, but it is highly immunogenic and is a potential serodiagnostic marker for Lyme borreliosis.
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INTRODUCTION
Borrelia burgdorferi, the pathogenic spirochete that causes Lyme dis-
ease, is a tick-borne parasitic bacteria whose natural reservoir is a
variety of small mammals and avian species.1 B. burgdorferi expresses
a large number of outer surface lipoproteins that are the major inter-
face in interacting with host environments. Accumulated evidence has
demonstrated that these surface lipoproteins play a central role for the
successful maintenance of B. burgdorferi within the enzootic life cycle
involving Ixodes ticks and mammals.1–3 Spirochetes differentially
regulate these surface lipoproteins during the transitions between ticks
and mammals.4–7 B. burgdorferi lipoproteins are also highly immuno-
genic, and some of the surface lipoproteins have been used as sero-
diagnostic markers.8–10
While much work has been focusing on surface lipoproteins, pro-
teome analysis has revealed that some classical cytosolic proteins of
B. burgdorferi are associated with membrane fractions.11,12 These
proteins are so-called moonlighting protein in which a single protein
has dual or moonlighting functions.13–16 One such protein is enolase,
a known cytosolic enzyme that catalyzes the conversion of 2-phos-
phoglycerate into phosphoenolpyruvate for glycolysis. However, a
fraction of enolase has been found on the cell surface of several micro-
organisms, where it interacts with extracellular matrix component
proteins and plays a role in pathogens’ colonization and dissemina-
tion.17–19 Recently, several reports showed that B. burgdorferi enolase
is associated with cell surface and outer membrane vesicles of spiro-
chetes.12,20,21 Borrelia enolase is capable of binding to plasminogen/
plasmin in vitro, which may assist spirochetes to disseminate during
mammalian infection. In addition, B. burgdorferi enolase also trig-
gered an antibody response, and such response reduced acquisition
of spirochetes by ticks from mice.21
Another moonlighting protein found in pathogenic bacteria is
elongation factor Tu (EF-Tu). EF-Tu is a cytosolic GTP binding pro-
tein and an essential component of protein synthesis apparatus.22 EF-
Tu also serves as a novel moonlighting protein that exhibits multiple
biological functions involved in bacterial pathogenesis. It is found on
the surface of several pathogenic bacteria and is involved in adhesion,
invasion, and modulation of the host immune system.23–31 For
example, surface EF-Tu of Mycoplasma pneumoniae serves as a fibro-
nectin binding protein and facilitates the interaction with extracellular
matrix.27 Surface EF-Tu from Leptospira interrogans, Streptococcus
pneumoniae, and Pseudomonas aeruginosa binds to the complement
regulators factor H and plasminogen and has been proposed to con-
tribute to tissue invasion and host immune evasion.23–25 Surface EF-
Tu in Franciscella tularensis interacts with nucleolin and plays a role in
adhesion and invasion of monocyte-like cells.26 Furthermore, pro-
teome analysis has demonstrated that EF-Tu is an immunogen that
elicits antibody response during infection by several bacteria.30,32,33
The B. burgdorferi genome has one copy of tuf gene (bb0476) which
encodes for EF-Tu.34 Since EF-Tu has been found on the surface in
other organisms and plays a role in pathogenesis, we investigated the
possible moonlighting nature of B. burgdorferi EF-Tu. We demon-
strated that EF-Tu is highly immunogenic in mice infected with
B. burgdorferi and in Lyme disease patients. Immunization of mice
with rEF-Tu did not elicit a protective response against challenge with
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B. burgdorferi. However, EF-Tu did not appear to be localized on the
surface of B. burgdorferi. Our results suggest that protoplasmic EF-Tu
is an immunoreactive protein that may be a potential serodiagnostic
marker during early stages of B. burgdorferi infection.
MATERIAL AND METHODS
Bacteria
Low-passage, virulent B. burgdorferi strain 5A4NP1 (kindly provided
by Hiroki Kawabata and Steven Norris, University of Texas Health
Science Center, Houston, USA) was derived fromwild-type strain B31
by inserting a kanamycin resistance marker in the restriction modi-
fication gene bbe02 on plasmid lp25.35 Strain B31-A3 (kindly provided
by Patricia Rosa, Rocky Mountain Laboratories, National Institute of
Allergy and Infectious Diseases, National Institutes of Health (NIH),
USA) is a clonal low-passage infectious strain which contains all of the
plasmids described for parental strain B31 MI except cp9 B31-MI.36
Spirochetes were grown using standard Barbour–Stoenner–Kelly II
(BSK-II) medium containing the relevant antibiotic. Cultures were
maintained at 37 6C, pH 7.5 in a 5% CO2 incubator and were passaged
no more than two times from the original stocks.
Recombinant protein
The B. burgdorferi tuf gene bb0476 encoding EF-Tu from strain B31
was amplified by polymerase chain reaction (PCR) using the primer
pair Sa-bb0476-5 (forward) and Sa-bb0476-3 (reverse; Table 1). The
resulting amplicon was cloned into pET100/D-TOPO (Invitrogen,
Carlsbard, CA, USA) to generate plasmid pSCEF-TuCT2, which was
then entirely sequenced on both strands to rule out the possible intro-
duction of undesired mutations during PCR and cloning procedures.
EF-Tu-63His fusion protein was expressed in Escherichia coli Rosetta
(DE3) (Novagen, Madison, WI, USA). Briefly, exponentially grown
cells (A600, 0.5) were induced for 5 h at 37 6C with 0.1 mM (final
concentration) of isopropyl-b-d-thiogalactopyranoside. Cells were
pelleted and resuspended in a buffer containing 400 mM NaCl, 40
mM NaH2PO4 (pH 7.2), 500 mM DTT, and 100 mM proteinase
inhibitor phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich, St.
Louis, MO, USA). Cells were then lysed by brief sonication and debris
was cleared by centrifugation. The resulting supernatant was loaded
onto nickel-charged resin (Ni NTA, Qiagen, Valencia, CA, USA) for
affinity purification. After washing, proteins were eluted with 500mM
imidazole and then concentrated with 40% ammonium sulfate.
Proteins were collected by centrifugation, dissolved in buffer solution
(50 mM potassium phosphate, 10% glycerol, 0.1 mM EDTA buffer),
and dialyzed against the same buffer overnight at 4 6C. The dialysate
was centrifuged at 50003g for 15min, and the supernatant was filtered
in 10 kDa molecular mass cutoff membranes (Fisher Scientific,
Pittsburgh, PA, USA) prior to use. Protein purity was assessed by
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Protein concentration wasmeasured using a Bradford protein
assay kit (Bio-Rad, Hercules, CA, USA).
Construction of a shuttle vector for constitutively expression
of EF-Tu
To constitutively express the wild-type tuf, the DNA fragment of tuf
was amplified by PCR from B. burgdorferi B31-A3 using primers
PRYY7 and PRYY8 with restriction enzyme sites NdeI and PstI and
a HA epitope tag sequence, respectively. The PCR products were
digested with NdeI and PstI and inserted into the pBSV2-derived
shuttle vector pJD55 under the control of a constitutive borrelial pro-
moter, PflaB. The resulting shuttle vector, pYY003, was verified by
sequencing and then transformed into B31-A3 as described prev-
iously.2 The transformants (B31-A3/PflaB-tuf-HA) were selected in
a 96-well tissue culture plates (200 mL/well) containing liquid BSK-
II medium and relevant antibiotics (200 mg/mL kanamycin). The level
of expression of EF-Tu in B. burgdorferi transformants was also veri-
fied by immunoblotting.
SDS-PAGE and immunoblotting
SDS-PAGE and immunoblotting were performed as previously
described.37 Monoclonal antibodies directed against OspA (14D2-27)
and the loading control FlaB (8H3-33)38 were used at a dilution of
1:1000 and 1:500, respectively. A polyclonal mouse antibody against
EF-Tu (1:15 000 dilution) was used to detect recombinant EF-Tu and
EF-Tu in B31 whole-cell lysates using nitrocellulose membranes (Bio-
Rad). HA.11 monoclonal antibody (1:1000; clone 16B12; Covance,
Princeton NJ, USA) was used to detect HA-tagged EF-Tu in whole-cell
lysates. OspA, FlaB, and/or EF-Tu antibodies were detected with either
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG sec-
ondary antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or HRP-conjugated goat anti-human IgM, IgG, and IgA second-
ary antibody (1:1000; Kirkegaard & Perry Laboratories Gaithersburg,
MD, USA). Detection of peroxidase activity was determined in mem-
branes using both 4-chloro-1-napthol and H2O2 (Fisher Scientific)
solution or an enhanced chemiluminenscent method (Pierce ECL
Western Blotting Substrate, Thermo Scientific, Rockford, IL, USA).
Sera from four C3H/HeN mice infected with 5A4NP1 (106 spiro-
chetes/mouse) were pooled and used to assess the appearance of anti-
body response against recombinant EF-Tu protein. Sera were diluted
1:600 in 13 PBS 20.05% Tween-20 (PBS-Tween) and incubated at
room temperature (RT) for 2 h with nitrocellulose membrane strips
containing approximately 500 ng of recombinant EF-Tu protein per
strip.
Lyme disease patient sera were from the Center for Disease Control
and Prevention (CDC) Lyme disease evaluation panel, which consists
of 42 serum samples (including both positive and negative). We used
sera from 10 Lyme disease patients that tested positive for Lyme dis-
ease by enzyme-linked immuno-sorbent assay (ELISA) and Western
blot. Control sera were collected fromhealth individuals in areas of the
USA where Lyme disease is not endemic. All human sera were diluted
1:100 in PBS-Tween for immunoblotting,39 as described above. Each
strip contains 500 ng of recombinant EF-Tu.
Quantitative PCR (qPCR)
For quantification of B. burgdorferiDNA in mice and ticks, total DNA
was isolated from joint tissue and fed larvae (3–6 data points for each
group, three tick per data point) using DNeasy blood and tissue kit as
Table 1 Primers used in the study
Primer Sequence (5’R 3’)
Sa-bb0476-5 CACCATGAAATTTAGGAGGTTAGTCATGGC
Sa-bb0476-3 CTATTCCAATATCTCAAGAATTCTTCCTG
PRYY7 GCAGCCATATGGCAAAAGAAGTTTTTCAA
PRYY8 CGTCTGCAGTTAAGCGTAATCTGGAACATCGTATGG
GTATTCCAATATCTCAAGAATTCTTCCT
qTactin-F CGGGACCTGACCGACTACCTGATG
qTactin-R CTCCTTGATGTCGCGGACAATTTC
flaB-XF F GCTCCTTCCTGTTGAACACCC
flaB-XF R CTTTTCTCTGGTGAGGGAGCTC
nidogen F CCAGCCACAGAATCACATCC
nidogen R GGACATACTCTGCTGCCATC
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described in themanufacturer’s protocols (Qiagen). qPCR of genomic
DNA was performed using the Platinum SYBR green qPCR SuperMix
(Invitrogen). The oligonucleotide primer pairs used to detect flaB,
mouse nidogen, and tick actin were flaB-XF F/R, nidogen F/R, and
qTactin-F/R, respectively (Table 1).40–42 Reactions were carried out
on an ABI Prism 7000 real-time PCR machine (Applied Biosystems,
Pleasanton, CA, USA). Calculations of DNA copy number of flaBwere
normalizedwith the copy numbers of either themouse nidogen gene or
the tick actin gene, as indicated in Results.
Proteinase K accessibility assay
Proteinase K (PK) accessibility assays were performed as described.43,44
Briefly, B. burgdorferi B31-A3 or B31-A3/PflaB-tuf-HA (1 3 108/mL)
were gently washed three times in PBS (pH 7.4) and collected by cent-
rifugation at 40003g for 30 min. Washed spirochetes were then gently
resuspended in 2.5 mL of PBS and split into five equal 500 mL volume
samples. Four samples were treated with proteinase K (25, 50, 100, or
200 mg of PK; Sigma, St Louis, MO) for 1 h at RT while one sample was
incubated with 13 phosphate-buffered saline (PBS) as a control. After
incubation, samples were treated with 10 mL of PMSF (Sigma) to inac-
tivate PK activity. Samples were subsequently pelleted by centrifugation
at 10 0003g for 10 min and resuspended in PBS for SDS-PAGE and
immunoblotting.
TX-114 phase partitioning
To determine whether EF-Tu has the amphiphilic properties expected
of a membrane protein, B. burgdorferi B31-A3 cells (109 organisms)
were harvested and phase-partitioned as described previously.45 The
resulting protein pellets were resuspended in PBS and subjected to
SDS-PAGE and immunoblot analysis using the polyclonal antibody
directed against EF-Tu or the monoclonal antibody against OspA,
which is a well-characterized amphiphilic lipoprotein.
Isolation of outer membrane vesicles
Isolation of the outermembrane vesicles (OMVs) of B. burgdorferiwas
performed as described.46,47 Briefly, 5 3 101021011 B. burgdorferi cells
were washed twice in 13 PBS (pH 7.4) containing 0.1% bovine serum
albumin (BSA), resuspended, and incubated on a rocker at RT for 2 h
in ice-cold 25 mM citrate buffer (pH 3.2) containing 0.1% BSA. The
resulting outer membrane vesicle and protoplasmic cylinder (PC)
fractions were separated and purified on a sucrose density gradient
as detailed.46 The OMVs vesicles were monitored for purity by immu-
noblotting using antibodies against OspA and FlaB.
Immunofluorescence assay (IFA)
To determine whether EF-Tu is surface-exposed, B31-A3 and B31-A3/
PflaB-tuf-HA spirochetes from mid-logarithmic phase cultures were
probed in solution as previously described.48,49 Briefly, unfixed live
spirochetes were incubated at RT for 1 h in blocking solution (2%BSA
in 13 PBS with 5 mM MgCL2) containing the primary antibodies of
interest. A polyclonal antibody against EF-Tu and a monoclonal anti-
body directed against HA.11 were used at a final dilution of 1:40 and
1:1000, respectively. Monoclonal antibodies directed against OspA
and FlaB were used at a final dilution of 1:40. After the primary
incubation, spirochetes were washed twice and gently resuspended
in blocking solution, and then 20 mL of cell mixtures were added on
silylated microscope slides and air dried (CEL Associates, Pearland,
TX, USA). Slides were then incubated with a 1:1000 dilution of
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch Inc, West Grove, PA, USA) for 1 h at
37 6C in a dark, humid chamber. Slides were gently washed with
blocking solution and then mounted with antifade light mounting
medium (Molecular Probes, Eugene, OR). As an additional control
for this unfixed IFA experiments, spirochetes were incubated for 1 h
with BacTrace FITC-conjugated goat anti-B. burgdorferi antibody
(Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) at a
1:100 dilution in blocking solution. The presence of fluorescent
spirochetes was confirmed with an Axio Imager.A2 fluorescence
microscope (Carl Zeiss, Jena, DE).
To detect the presence of EF-Tu, FlaB, and OspA in spirochetes, we
also used an alternative IFA method48,50 in which spirochetes were
placed onto silylated slides, air dried, and fixed and permeabilized by
immersion in acetone for 10min. This fixed IFAmethod was also used
to detect the presence of fixed spirochetes in smears of fed tick larvae.50
Slides were then incubated at 37 6C for 1 h with blocking solution
(PBS-Tween 20 with 5% goat serum) in a humid chamber. Fixed
spirochetes were incubated at RT for 1 h in blocking solution contain-
ing the primary antibodies of interest and then followed by washes and
incubation with a secondary antibody, as described above.
Active immunization and infection studies
Groups of C3H/HeN mice were immunized with 50 mg recombinant
EF-Tu in PBS (1:1) with adjuvant (complete Freund’s adjuvant;
Sigma). Mice received two boosts of 50 mg recombinant EF-Tu in
PBS (1:1) with incomplete Freund’s adjuvant (Sigma) at 14-day inter-
vals. One week after the final boost, mice were inoculated with B.
burgdorferi strain 5A4NP1 with a dose of 104 spirochetes per mouse.
Mice were euthanized at ether two weeks or five weeks post-inocu-
lation. Infectivity was assessed by culturing ear pinna, joints, and heart
tissues in BSK-II medium supplemented with the relevant antibiotic
(200 mg/mL kanamycin) as well as the Borrelia antibiotic cocktail
(50 mg/mL rifampicin, 20 mg/mL phosphomycin and 2.5 mg/mL
amphotericin). A single growth-positive culture occurred within
one week post-harvest and was used as the criterion to determine
positive mouse infection. All experiments were performed with the
approval of the Indiana University Institutional Animal Care and Use
Committee.
For tick studies, pathogen-free Ixodes scapularis larvae were
obtained from the Tick-Rearing Center at Oklahoma State
University (Stillwater, OK, USA). The tick-mouse experiments were
conducted in the Vector-borne Diseases Laboratory at Indiana
University School of Medicine (IUSM). At three weeks post-challenge
with B. burgdorferi strain 5A4NP1, unfed larvae were placed on
immunized mice (,50 larvae per mouse). At 72–96 h, these larvae
had fully engorged and naturally dropped off the mice. A subset of fed
larvae was subjected to IFA and qPCR analysis to determine B. burg-
dorferi acquisition and loads. The remaining fed larvae were main-
tained in a humidified chamber and allowed to molt to the nymphal
stage (about five weeks). Two months after molting, unfed nymphs
were then allowed to feed on immunized mice (,three nymphs per
mouse) and collected within 48 h after repletion. Two weeks after
tick feeding, mouse tissues were collected and tested for infection by
culture as described above.
Statistics
Data are presented as the mean 6 SEM and were analyzed with the
Prism 5.0 statistical program (GraphPad Software, Inc., San Diego,
CA, USA). Statistical comparisons were performed by using a Student
t test. A P valuef 0.05 was considered significant.
B. burgdorferi EF-Tu is an immunogenic antigen
SE Carrasco et al
3
Emerging Microbes and Infections
RESULTS
B. burgdorferi EF-Tu is recognized by mouse and human sera
during infection
To determine whether B. burgdorferi EF-Tu is immunogenic during
mammalian infection, we first purified recombinant EF-Tu (rEF-Tu)
from E. coli (Figure 1A). We then infected mice sera from infected
mice with B. burgdorferi were tested for reactivity to recombinant EF-
Tu (rEF-Tu). We found that antibodies against rEF-Tu were detect-
able in the serum of infected mice as early as two weeks after needle
inoculation. Seroreactivity to rEF-Tuwas detectable even after 6 weeks
or 11 weeks (data not shown) post-infection (Figure 1B), suggesting
that B. burgdorferi anti-EF-Tu antibodies are maintained after two
months of infection. This result indicates that B. burgdorferi EF-Tu
is an antigenic protein that elicits antibody response during murine
infection.
To assess whether Lyme disease patients elicit antibody response
against EF-Tu of B. burgdorferi, rEF-Tu was immunoblotted with
Lyme disease patient sera from CDC Lyme disease evaluation panel.
We found that 70% of samples tested (seven out ten patient sera) were
reactive to rEF-Tu (Figure 1C and Table 2). Seroreactivity to rEF-Tu
was detected in samples from seropositive patients with different clin-
ical manifestations associated with Lyme disease, including erythema
migrans, arthritis, and/or neurologic symptoms. Four samples exhib-
ited strong reactivity to rEF-TU and were also seropositive by ELISA
and Western blot with presence of IgM and IgG antibodies against
B. burgdorferi antigens (Table 2). Two samples exhibited strong react-
ivity to rEF-Tu were also seropositive by ELISA andWestern blot with
presence of IgM antibodies against B. burgdorferi antigens (Table 2).
One sample was also reactive to rEF-TU and tested positive by ELISA
and Western blot with evidence of IgG when blotted against B. burg-
dorferi antigens (Table 2). These results indicate that B. burgdorferi
EF-Tu is an attractive serological target for Lyme disease diagnosis.
Active immunization with rEF-Tu does not protect mice from
B. burgdorferi infection
The finding of EF-Tu as an antigenic protein prompted us to assess
whether immunization of mice with rEF-Tu could elicit protective
immunity against B. burgdorferi infection. C3H/HeNmice were actively
immunizedwith rEF-Tu or adjuvant alone (control), and antibody titers
were verified by immunoblot assays. Mice developed an antibody titer
to rEF-Tu of 1:15,000 before intradermal challenged with infectious
B. burgdorferi strain 5A4NP1 (104 spirochetes/mouse). Two and five
weeks post-challenge, mouse ear punch biopsies, tibiotarsal joints, and
hearts were cultured for detection of B. burgdorferi. Culture results
showed that all mice were infected with B. burgdorferi (Table 3). To
further quantify the spirochete load in mice, joint tissues were subjected
to DNA extraction and real-time qPCR. No significant difference in
spirochete loads were detected in joints from immunized mice when
compared to control mice (Figure 2A). Thus, active immunization with
rEF-Tudoes not protectmice uponneedle inoculatedwithB. burgdorferi.
Needle inoculation and tick challenge of mice may have profoundly
different infection outcomes,51 as the in vitro cultivation conditions
are different form the environments in which spirochetes encounter
during tick feeding. Therefore, we next challenged a second group of
EF-Tu-immunized mice with nymphal ticks carrying B. burgdorferi.
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Figure 1 Serologic reactivity of recombinant EF-Tu (rEF-Tu) in infected mice and Lyme disease patients. (A) SDS-PAGE showing purified recombinant EF-Tu protein.
Predicted size and observed size forB. burgdorferi EF-Tu is 43 kDa and 47 kDa, respectively. (B) Immunoblotting of rEF-Tu using sera collected from C3H/HeNmice
infected with B. burgdorferi strain 5A4NP1. Mouse sera used were collected at 2, 3, 4, 6 weeks of post-infection (1:600 dilution). *, HS stands for hyperimmune sera
from mice immunized with rEF-Tu (aEF-Tu, 1:10000 dilution). ^, N stands for sera from naı¨ve mice (1:600 dilution). (C) Representative immunoblotting results
showing serologic reactivity of rEF-Tu in Lyme disease patients. Strips C-K are rEF-Tu probedwith sera from ten different Lyme disease patients randomly selected from
the CDC Lyme disease patient sera panel (1:100 dilution).
Table 2 Seroreactivity of Lyme disease patient serum against
recombinant EF-Tu protein
Reactivitya
Western blot
Serum IDb EF-Tua ELISA IgM IgG
902668 (C) 1 1 1 1
920057 (D) 1 1 1 1
911222 (E) 1 1 1 2
902111 (F) 1 1 2 1
911351 (G) 1 1 1 2
910544 (H) 1 1 1 1
911348 (I) 1 1 1 1
910865 (J) 2 1 1 1
931414 (K) 2 1 1 1
910533 2 1 1 1
a 1: Seropositive and 2: seronegative results. All Lyme disease patient samples
tested positive to ELISA and/or Western blot. Sera from three healthy donors were
used as negative controls for immunoblotting as indicated in material and methods.
b Serum identification number used by the CDC Lyme disease evaluation panel, and
letters in parentheses indicated strip identification from immunoblot results in
Figure 1C.
B. burgdorferi EF-Tu is an immunogenic antigen
SE Carrasco et al
4
Emerging Microbes and Infections
Similar to what was observed for needle inoculation, all mouse tissues
were culture positive for spirochetes two weeks after tick feeding
(Table 3). These results indicate that although B. burgdorferi infection
elicits antibody response against EF-Tu, immunization with rEF-Tu
does not protect mice from B. burgdorferi infection by either needle
inoculation or natural tick infection.
Antibody against EF-Tu does not affect spirochetal survival or
migration in ticks
It is well known that antibodies against surface antigens of B. burgdor-
feri are capable of killing spirochetes in ticks during tick feeding or
block spirochetal migration between mice and ticks.21,52,53 To deter-
mine whether EF-Tu antibody could influence acquisition of spiro-
chetal survival ormigration in ticks, naı¨ve larval ticks were fed onmice
that were immunized with rEF-Tu and infected with B. burgdorferi as
described above. Ticks were allowed to fully engorge, and then col-
lected and subjected to DNA extraction and qPCR analyses. No sig-
nificant differences in spirochete loads were detected in larvae fed on
immunized and control mice (Figure 2B). IFA using anti-B. burgdor-
feri antibody also did not observe noticeable differences in the number
of spirochetes in tick-smears collected from the two groups (data not
shown). These results indicate that EF-Tu antibodies did not interfere
with B. burgdorferi acquisition by ticks from mice nor spirochetal
replication in ticks.
B. burgdorferi EF-Tu is not surface-exposed
To investigate whether EF-Tu can be found on the surface of B. burg-
dorferi as observed in several other bacteria,15,16,24 we first performed
IFA assays (Figure 3A). Fixed (top panel) or unfixed (lower panel)
spirochetes were probedwith antibody directed against EF-Tu, or with
antibody against the known surface lipoprotein OspA or with anti-
body against the periplasmic protein FlaB. As shown in the top panel
of Figure 3A, all three proteins were detected in fixed spirochetes,
suggesting that they are readily expressed. In unfixed samples, OspA
was readily detected. Both FlaB and EF-Tu were not detected with the
corresponding antibodies (Figure 3A, lower panel), suggesting that
B. burgdorferi EF-Tu was not surface-localized.
We also performed proteinase K treatment experiment to assess the
surface localization of EF-Tu. Proteinase K can degrade surface-exposed
proteins (e.g., OspA) in B. burgdorferi, whereas subsurface proteins are
protected from proteolysis (e.g., FlaB). The results showed that the bulk
of OspA was degraded by proteinase K (100–200 mg/mL, Figure 3B),
while the levels of FlaB and EF-Tu were not affected by proteinase K
treatment. This result is consistent with the above IFA finding that EF-
Tu is not localized on the surface of B. burgdorferi.
To further evaluate whether B. burgdorferi EF-Tu is surface-
exposed, we constructed a B. burgdorferi strain that overexpresses
EF-Tu. We reasoned that the fraction of surface EF-Tu may be too
low to detect in wild-type strain and if so, overexpressing EF-Tu
would amplify the signal and allow detection of such population of
EF-Tu. Accordingly, a shuttle vector carrying a tuf gene under the
control of a flaB promoter (Figure 4A) was transformed into the
wild-type B. burgdorferi strain B31, resulting in a B. burgdorferi strain
(B31-A3/PflaB-tuf-HA) which overexpressed EF-Tu (fused with HA
tag at the C terminus; Figure 4B and 4C, the band corresponding to
EF-Tu-HA was indicated by arrow). This EF-Tu overexpressing strain
was then subjected to IFA and proteinase K protection experiments as
described above. The IFA result showed that no surface EF-Tu was
detected in B. burgdorferi even with overexpression (data not shown).
Consistent with this observation, the proteinase K protection result
also showed no obvious change of the level of EF-Tu-HA upon pro-
teinase K treatment, i.e., EF-Tu-HAwas not accessible by proteinase K
(Figure 3C). Taken together, these results suggest that EF-Tu is not
surface-localized in B. burgdorferi.
EF-Tu is a PC-associated protein in B. burgdorferi
To further examine the cellular localization of EF-Tu, we next per-
formed Triton X-114 (TX-114) phase partitioning studies with B. burg-
dorferi cells to separate fractions based on their amphiphilic properties.
As expected, OspA, a known outer surface lipoprotein, was found in the
detergent (membrane-enriched) phase (Figure 5A). In contrast, EF-Tu
was not detected in the detergent phase of B. burgdorferi and was par-
titioned exclusively into the soluble aqueous (non-membrane-
enriched) fractions. These data suggest that EF-Tu is a cytoplasmic
protein and not associated with membrane of B. burgdorferi.
Because B. burgdorferi is capable to release immunogenic surface
proteins as well as cytoplasmic proteins via OMVs,12,46,54 we next
assessed whether EF-Tu could be part of the protein cargo that is
released inOMVs and contributes to its immunogenicity. Outermem-
brane vesicles and PC inner membrane associated proteins were
obtained by sucrose density gradient centrifugation and subjected to
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Figure 2 Active immunization with rEF-Tu does not protect mice from B. burg-
dorferi, and anti-EF-Tu antibody does not affect spirochetal survival and migra-
tion in in the tick vector. (A) Quantitation of spirochete load in mice. Tibio-tarsal
joints from mice immunized with rEF-Tu or non-immunized mice (labeled as
‘Adjuvant’) were subjected to qPCR analyses (n 5 4 mice/group). The B. burg-
dorferi flaB gene was used as target, and the levels were normalized with the
mouse Nidogen gene. Data denote the mean 6 the standard error (SEM) from
two separate experiments. Differences between mice immunized with rEF-Tu
and controls were analyzed using a Student t test (P value f 0.05). (B) qPCR
analyses of spirochete load in larvae fed on B. burgdorferi-infected mice that
were either immunized with EF-Tu (which contains high levels of anti-EF-Tu
antibodies) or non-immunized. Bars represent the mean 6 SEM from 18 fed
larval ticks collected from immunized mice and 9 fed larval ticks collected from
controls (n 5 2 mice/group). Data are representative of two separate experi-
ments. Copies of the flaB genes were normalized with tick actin gene.
Table 3 Culture results of mice immunized with rEF-TU. Culture
results expressed as number of mice infected/total number of
mice tested
Method of inoculation Group Culture resulta
Needle Adjuvant 4/4
Adjuvant 1 rEF-TU 6/6
Nymphal ticks Adjuvant 2/2
Adjuvant 1 rEF-TU 2/2
aMice were euthanized at either two or five weeks post-challenge. Isolation of
spirochetes were attempted from ear pinna, tibiotarsal joint, and heart base.
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immunoblot analyses. As expected, OspAwas predominantly detected
in the OMV fraction (Figure 5B). On the other hand, EF-Tu protein
was primarily associated with the PC inner membrane-enriched frac-
tion; only a trace amount was detected in the OMV sample
(Figure 5B). Collectively, our data show that EF-Tu localizes primarily
in the cytoplasm associated with the PC structures.
DISCUSSION
In recent years, a growing number of highly conserved bacterial pro-
teins that are commonly involved in metabolic regulation or cell stress
responses have shown additional biological functions involved in bac-
terial adaptation, virulence, and/or immune modulation.15,16 One
such moonlighting protein is enolase that localizes on the surface of
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Figure 3 B. burgdorferi EF-Tu is not surface-localized. (A) IFAs of fixed (top panels) or unfixed (bottom panels) wild-type B. burgdorferi strain B31-A3 probed with
monoclonal antibodies directed against outer surface protein OspA, periplasmic protein FlaB, or EF-Tu as primary antibodies, and FITC-conjugated goat anti-mouse
antibody as secondary antibodies. (B) Proteinase K protection assay of wild-type B. burgdorferi. Intact cells were incubated with proteinase K (200 mg/mL) for 1 h.
Washed cells were then subjected immunoblotting using a mixture of antibodies against OspA, FlaB, and EF-Tu. (C) Proteinase K protection assay of B. burgdorferi
overexpressing EF-Tu. Intact cells were incubated with proteinase K (25, 50, 100, or 200 mg/mL) for 1 h and then subjected to SDS-PAGE (left panel and black arrow
indicates the observed size of B. burgdorferi EF-Tu) or immunoblotting using a mixture of antibodies against OspA, FlaB, and EF-Tu (right panel). Data are
representative of four separate experiments.
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Figure 4 Construction of theB. burgdorferi strain overexpressing EF-Tu. (A) Diagram of the shuttle vector pYY003 carrying a tuf gene under the control of a strong and
constitutive flaB promoter. (B) Coomassie-stained gel showing overexpression of EF-Tu. Lane 1, wild-type strain B31-A3; lane 2, B31-A3/PflaB-tuf-HA. The band
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B. burgdorferi and has properties associated with spirochetal adhesion
and immunogenicity. In this study, we showed that EF-Tu of B. burg-
dorferi does not appear to be exposed on the cell surface. However, it
elicits antibody response in mice as well as in Lyme disease patients,
suggesting to be a potential serodiagnostic marker for Lyme disease.
According to the US Centers for Disease Control recommendation,
serodiagnosis of Lyme disease should be performed using a two-tiered
approach, an ELISA with B. burgdorferi whole-cell lysates, followed by
immunoblot confirmation with purified antigens of B. burgdorferi.55
This method was established in 1995 and there are several shortcom-
ings including insensitive detection of early infection and high false
positive rates. Early diagnosis is important, as the treatment is most
effective during early infection of B. burgdorferi, which prevents
development of complicated post-treatment Lyme disease syndrome.
Thus, new antigens, especially antigens that may be used for early
diagnosis of Lyme disease, are urgently needed. Our immunoblotting
results showed that EF-Tu was recognized by antibodies from mouse
sera collected at the early and disseminated stage of infection. In addi-
tion, 7 out of 10 patients with a history of prior tick exposure or
infection and early and late clinical manifestations were seroreactive
to rEF-Tu. Thus, our findings suggest that rEF-Tu is recognized by IgG
antibodies as this protein reacted with mouse and human sera col-
lected at different stages of Lyme borreliosis. rEF-Tu triggered an
antibody response within the first four weeks post-challenge, suggest-
ing that EF-Tu is a potential early marker of Lyme borreliosis.
Interestingly, two Lyme disease patients who exclusively had IgM
antibodies to B. burgdorferi antigens showed seroreactivity to rEF-
Tu. Although a small number IgM seropositive samples were tested,
our data suggest the possibility thatB. burgdorferiEF-Tu could elicit an
antibody response shortly after exposure to spirochetes. This obser-
vation is consistent with a previous study showing thatBorrelia hermsii
EF-Tu was strongly reactive with IgM antibodies during early spiro-
chetal infection in mice.56 Given EF-Tu is a conserved protein, we also
analyzed potential cross reactivity of B. burgdorferi EF-Tu with anti-
bodies from other pathogens: B. burgdorferi EF-Tu shares 50–65%
identity with EF-Tu from other spirochetal pathogens and non-
spirochetal pathogens. Thus, future studies are needed to evaluate
whether the immunogenic epitopes in the variable region from
B. burgdorferi EF-Tu could be used as potential serodiagnosticmarkers
of early Lyme borreliosis.
Although B. burgdorferi EF-Tu appeared to elicit an antibody res-
ponse in vivo, several lines of evidences suggest that EF-Tu is not
surface-localized. First, the active immunization experiments showed
that these anti-EF-Tu antibodies were not bactericidal during Lyme
borreliosis as they were unable to reduce spirochetal burden in joints
or in engorged tick larvae from immunized mice. Second, the protei-
nase K and immunofluorescent microscopy findings showed that EF-
Tu was not on cell surface. Third, our findings showed that B. burg-
dorferi EF-Tu predominantly localizes in PC fractions andmay present
in OMV fractions in small quantities. B. burgdorferi periplasmic and
cytoplasmic proteins have shown to be immunogenic in Lyme disease
patients.12,57–59 Of these proteins, FlaB (41 KDa) and FlaA are highly
reactive to IgM antibodies during the first four weeks of illness, and the
protoplasmic protein p83/100 (83–100 kDa) is highly reactive to IgG
antibodies in patients with late Lyme borreliosis.57,60
In conclusion, our findings demonstrate that B. burgdorferi EF-Tu is
not surface-localized but is highly immunogenic that triggers an anti-
body response during Lyme borreliosis. Thus, B. burgdorferi EF-Tu is a
potential candidate for serodiagnosis of Lyme borreliosis.
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